The Role of Fish Oil in Modulating Metabolic Disorders: Implications for Cardiovascular Health, Endothelial Dysfunction Biomarkers, and Hypercholesterolemia Authors: Hessah M. Al-Muzafar, Kamal A. Amin Published: 2026 ABSTRACT Background:Hypercholesterolemia is a significant risk factor for various metabolic disorders, such as diabetes, cardiovascular disease (CVD), and atherosclerosis, which contribute to morbidity and mortality worldwide. Fish intake has been associated with a lower risk of CVD; however, the administration of n-3 long-chain polyunsaturated fatty acids (LC-PUFAs) has shown limited effects on cholesterol levels.Aims:This study aimed to investigate the role of fish oil in maintaining a healthy metabolism; explore the impact of hypercholesterolemia on oxidative stress, endothelial dysfunction, and inflammatory biomarkers; and determine the biochemical relationships among lipid profiles, inflammatory mediators, and endothelial dysfunction biomarkers. Additionally, we compared the potential roles and mechanisms of action of fish oil and atorvastatin in the treatment and prevention of cardiovascular events.Methods:Eighty rats, weighing 100–150 g, were divided into five equal groups. The first group (control) was fed a standard diet. The second group was fed a high-cholesterol diet (HCD) for 8 weeks to induce hypercholesterolemia. The third group was given HCD supplemented with fish oil. The fourth group received HCD along with 20 mg of atorvastatin. Blood and tissue samples were analyzed to measure serum lipid profiles, including triglycerides (TG), cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and homocysteine levels. Inflammatory mediators (C-reactive protein, TNF, IL-6) and endothelial dysfunction markers (nitric oxide, nitric oxide synthase) were also measured. The statistical analysis method used for the study was one-way analysis of variance (ANOVA).Results:Compared to the control group, the final body weight and mean body weight gain were significantly greater in the HCD group. The HCD-fed rats exhibited increased levels of serum lipids, including LDL, TG, total cholesterol (TC), and HDL (P < 0.05), as well as elevated heart function markers (LDH and CK-MB), homocysteine, and inflammatory markers (TNF and CRP). These changes were ameliorated with the administration of atorvastatin and fish oil. HCD increased the levels of nitric oxide synthase and VCAM, while the administration of fish oil improved these markers.Conclusions:Fish oil effectively ameliorates hypercholesterolemia-induced dyslipidemia and inhibits inflammatory biomarkers. Additionally, it lowers cardiac biomarkers, potentially reducing the risk of inflammation, arteriosclerosis, and vascular endothelial dysfunction. These beneficial effects may be attributed to the active components in fish oil. We suggest that fish oils could be used as functional dietary ingredients or supplements to manage the risk of developing CVD. Overall, this study contributes new insights into the biochemical relationships between lipid metabolism, inflammation, and vascular health, while providing a comparative evaluation of fish oil versus atorvastatin in cardiovascular protection. Introduction A Western diet, particularly one rich in cholesterol, can increase hyperlipidemia and negatively affect endothelial function, both of which are major risk factors for various metabolic disorders, including diabetes, cardiovascular disease (CVD), and atherosclerosis.[1] Hypercholesterolemia, a condition characterized by elevated levels of cholesterol in the bloodstream, is a significant public health concern due to its strong association with the development of cardiovascular diseases. Cardiovascular disease is the leading cause of death globally, and hypercholesterolemia is a primary risk factor for this condition. Hyperlipidemia, which encompasses both elevated cholesterol and triglycerides, is the second most common chronic condition seen by physicians in nongovernment ambulatory care settings, underscoring the importance of understanding and effectively managing this condition. Hypercholesterolemia remains a leading cause of morbidity and mortality worldwide, despite advancements in primary and secondary prevention in recent decades.[2] However, many cholesterol-lowering drugs are associated with side effects, making fish oil an attractive alternative. Fish oil offers minimal side effects, low cost, good patient acceptability, and cost-effectiveness, suggesting its potential as a therapeutic option for managing hypercholesterolemia. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), particularly those derived from fish oil, are beneficial to human health and can help ameliorate metabolic diseases. It is hypothesized that the beneficial effects of these fatty acids could be enhanced when they are combined with other n-3 PUFAs.[3] Lipoproteins are the primary carriers of cholesterol, and altered lipoprotein levels are a consequence of atherosclerosis and cardiovascular disorders. The cholesterol content in various lipoproteins and apolipoproteins is associated with indicators of atherosclerosis, blood pressure, C-reactive protein (CRP), and coronary heart disease. These factors also influence the risk of heart failure, type 2 diabetes mellitus (T2DM), Alzheimer’s disease, and inflammatory bowel disease. Many observed effects appear to act independently of LDL-C, HDL-C, and TG, supporting the need to target lipid fractions beyond LDL-C for disease prevention.[4] Blood cholesterol and lipoprotein concentrations can be restored using medications that effectively block the intestinal absorption of excess dietary lipids.[5] However, while drugs may be effective, they can also induce severe side effects.[6] Statins, for example, which inhibit cholesterol biosynthesis, can cause muscle pain.[7] The side effects of commonly used drugs underscore the need for alternative approaches to prevent the progression of CVD. Dietary bioactive compounds offer a promising strategy to manage hypercholesterolemia as they act directly on the intestine.[89] Certain fatty acids can also lower the risk of CVD by increasing the proportion of small high-density lipoprotein (HDL) particles, which reduce cholesterol overload and enhance the cholesterol efflux capacity of the particles.[10] Among these fatty acids, long-chain omega-3 fatty acids, particularly eicosapentaenoic acid (EPA, 20:5 n − 3) and docosahexaenoic acid (DHA, 22:6 n − 3), are known to be effective in controlling CVDs.[1112] In recent years, there has been growing interest in the potential benefits of fish oil supplementation, specifically omega-3 fatty acids, for managing these conditions.[13] Fish oil, derived from fatty fish such as salmon, mackerel, and sardines, is rich in omega-3 fatty acids, particularly EPA and DHA.[14] These omega-3 fatty acids have been extensively studied for their cardiovascular benefits, including anti-inflammatory, antiplatelet, and triglyceride-lowering properties, all of which contribute to improved cardiovascular health. Consumption of long-chain omega-3 fatty acids has the potential to slow the progression of cardiovascular diseases.[15] Additionally, fish oils are widely available and have minimal known side effects.[16] Our research could help bridge the gap in understanding the role of fish oil in preventing and managing cardiovascular diseases, hypercholesterolemia, and metabolic disorders. By addressing the mechanisms behind its effects on endothelial function, lipid profiles, and inflammatory processes, we provide valuable evidence to support or refine current guidelines on omega-3 fatty acid supplementation, particularly for those at risk of metabolic and cardiovascular diseases. Moreover, identifying the most effective use of fish oil based on individual health characteristics could lead to more personalized and targeted therapies in the future. The use of fish oil and atorvastatin as potential agents for treating hypercholesterolemia and related problems has gained importance. Therefore, our study aimed to establish a model of hypercholesterolemia and investigate the effects of fish oil on lipid profiles, proinflammatory biomarkers, and endothelial dysfunction in maintaining healthy metabolism in rats fed a high-cholesterol diet. Furthermore, we aimed to explore the biochemical relationships among lipid profiles, inflammatory mediators, and endothelial dysfunction biomarkers. Finally, we compared the potential roles and mechanisms of fish oil with atorvastatin in the treatment and prevention of atherosclerosis. Materials and Methods Materials Diet: Two types of diets were used: a control rat chow diet and a special high-cholesterol diet (HCD), containing 2% cholesterol and 0.4% bile acid, for the induction of hypercholesterolemia in rats. Experimental Animals: One hundred rats, weighing 100–150 g, were obtained from the Institute for Research and Medical Consultation (IRMC). The rats were allowed to acclimate for 1 week before the experiment began and were housed individually in plastic cages at room temperature (27°C) under a 12-hour light/dark cycle in the laboratory of IRMC, University of Imam Abdulrahman Bin Faisal. Drugs for treatment Atorvastatin: Atorvastatin (20 mg) was dissolved in distilled water (D.W.), and each rat was given 1 ml per os, corresponding to a dose of 0.7 mg/kg (0.1 mg/rat/day) by stomach tube. Atorvastatin was purchased from Jamjoom Pharmaceuticals Co. Ltd., Jeddah, Saudi Arabia. It served as a reference treatment for cholesterol to compare with fish oil. Fish Oil: Fish oil was given as a capsule at a dose of 100 mg/kg body weight (BWt). It was purchased from the local GNC market in Dammam city. Each GNC One enteric-coated soft gel capsule contains 900 mg of omega-3 fatty acids, including 647 mg of eicosapentaenoic acid (EPA) and 253 mg of docosahexaenoic acid (DHA). II. Methods This experimental study was approved by the Committee of Scientific Ethics at Imam Abdulrahman Bin Faisal University and was conducted according to its guidelines (IRB number: 201510,119). Experimental design and animal grouping The experiments were carried out over 12 weeks, including 8 weeks for the induction of hypercholesterolemia and 4 weeks of treatment. One hundred rats were used in the study. They were randomly allocated to different groups and divided into five equal groups: Group 1 (Control), which was fed a normal diet; Group 2 (HCD): Fed a high-cholesterol diet (HCD) for 8 weeks to induce hypercholesterolemia; Group 3 (HCD + Fish Oil): Fed an HCD supplemented with fish oil; Group 4 (HCD + Atorvastatin): Fed an HCD supplemented with atorvastatin. Blood and tissue sampling Blood Sampling: Blood samples were collected from the medial canthus of the eye using a microhematocrit capillary tube while the rats were fasting. Blood was collected into dry glass centrifuge tubes, allowed to coagulate at room temperature, and then centrifuged at 3500 rpm for 20 minutes to separate the serum. The nonhemolyzed supernatant serum was carefully transferred using clean, dry disposable plastic syringes and stored at -80°C for subsequent biochemical analyses.Tissue Sampling: At the end of the experiment, rats were sacrificed by decapitation. An abdominal incision was made immediately after blood collection to obtain the liver, heart, and kidneys. These organs were removed, washed with saline, and dried on filter paper. Approximately 1 g of each organ was homogenized in 10 ml of saline and centrifuged, and the supernatant was stored at -80°C for biochemical analysis. Blood Sampling: Blood samples were collected from the medial canthus of the eye using a microhematocrit capillary tube while the rats were fasting. Blood was collected into dry glass centrifuge tubes, allowed to coagulate at room temperature, and then centrifuged at 3500 rpm for 20 minutes to separate the serum. The nonhemolyzed supernatant serum was carefully transferred using clean, dry disposable plastic syringes and stored at -80°C for subsequent biochemical analyses. Blood Sampling: Blood samples were collected from the medial canthus of the eye using a microhematocrit capillary tube while the rats were fasting. Blood was collected into dry glass centrifuge tubes, allowed to coagulate at room temperature, and then centrifuged at 3500 rpm for 20 minutes to separate the serum. The nonhemolyzed supernatant serum was carefully transferred using clean, dry disposable plastic syringes and stored at -80°C for subsequent biochemical analyses. Tissue Sampling: At the end of the experiment, rats were sacrificed by decapitation. An abdominal incision was made immediately after blood collection to obtain the liver, heart, and kidneys. These organs were removed, washed with saline, and dried on filter paper. Approximately 1 g of each organ was homogenized in 10 ml of saline and centrifuged, and the supernatant was stored at -80°C for biochemical analysis. Tissue Sampling: At the end of the experiment, rats were sacrificed by decapitation. An abdominal incision was made immediately after blood collection to obtain the liver, heart, and kidneys. These organs were removed, washed with saline, and dried on filter paper. Approximately 1 g of each organ was homogenized in 10 ml of saline and centrifuged, and the supernatant was stored at -80°C for biochemical analysis. Biochemical analyses of serum The following biochemical analyses were performed on blood samples: Lipid profile: triglycerides (TG), cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels. Endothelial dysfunction markers: nitric oxide synthase and VCAM (vascular cell adhesion molecule). Inflammatory markers: C-reactive protein (CRP), TNF (tumor necrosis factor), and IL-6 (interleukin-6). Cardiovascular function markers: LDH (lactate dehydrogenase), CK (creatine kinase), and homocysteine. Statistical analysis Data were analyzed using one-way analysis of variance (ANOVA) followed by the Tukey–Kramer method for post hoc analysis. A P value of <0.05 was considered statistically significant. GraphPad Prism 6 software (San Diego, CA, USA) was used for statistical analysis. Data are presented as the mean ± SEM. Results No pathological changes were observed in the appearance or behavior of the animals during the experiment. A high-cholesterol diet, along with cholic acid, successfully induced hypercholesterolemia. Food Intake and Body Weight: As shown in Figure 1, the high-cholesterol diet (HCD) group exhibited a decrease in food intake compared to the normal group, while the body weight and mean body weight gain were significantly greater in the HCD-fed rats compared to the control rats [Table 1]. Changes in food intake in normal and HCD groups during weeks of the experiment Table 1Effect of fish oil and atorvastatin on body weight measurement HCD-fed ratsNormalHCDHCD + ATORHCD + Fish oilInitial body weight137.83±4.52141.25±2.22*136136.17Mean Body weight gain7.82±29.49±2.08*4.34±2.995.04±1.89These values represent means and standard errors, *indicate significant variations at P<0.05 Effect of fish oil and atorvastatin on body weight measurement HCD-fed rats These values represent means and standard errors, *indicate significant variations at P<0.05 Lipid Profile: Figures 2a-d show that the HCD diet induced a significant increase in cholesterol and LDL levels (P < 0.05), while there were no significant effects on HDL and triglycerides (TG) when compared to the normal group. The administration of atorvastatin or fish oil ameliorated the elevated cholesterol and LDL levels induced by the HCD, with no effects observed on HDL and TG levels. Effect of atorvastatin and fish oil on lipid profiles in HCD-fed rats. Panels show changes in (a) total cholesterol, (b) LDL-C, (c) HDL-C, (d) triglycerides levels. Each bar represents the mean ± standard error. Different treatment groups (e.g., control, HCD, HCD + atorvastatin, HCD + fish oil, combination therapy) are shown using distinct colored bars. Significant differences (P < 0.05) are indicated by different superscript letters above the bars Cardiac Biomarkers: The cardiac biomarker analysis revealed a significant increase (P < 0.05) in homocysteine levels in the HCD group compared to the normal group. Atorvastatin significantly improved these changes, whereas fish oil reduced homocysteine levels. No significant changes were observed in LDH and CK-MB levels across the groups [Figure 3]. Effect of atorvastatin and fish oil on cardiac biomarkers in HCD-fed rats. (a) LDH (ng/ml), (b) homocysteine (nM), and (c) CK-MB (ng/ml) levels are shown. Each bar represents the mean ± standard error. Different treatment groups are represented by distinct colored bars (control, HCD, HCD + atorvastatin, HCD + fish oil), and significant differences (P < 0.05) are indicated by different superscript letters above the bars Inflammatory Markers: Figure 4 shows that the inflammatory markers CRP and TNF were elevated in the HCD group compared to the normal group. Both atorvastatin and fish oil significantly (P < 0.05) ameliorated these inflammatory changes. Effect of atorvastatin and fish oil on inflammatory biomarkers (CRP (ng/ml), TNFα (pg/ml)) in HCD-fed rats. These values represent means and standard errors; the different superscript letters mean a significant difference at P < 0.05 Endothelial Dysfunction Markers: Figure 5 demonstrates elevated levels of nitric oxide synthase (NOS) and VCAM in the HCD group compared to the normal group. Both atorvastatin and fish oil improved these markers at a significant level (P > 0.05). Effect of aAtorvastatine, and fish oil on eEndothelial dysfunction biomarkers (NOS (µIU/ml) and VICAM1 (pg/ml)) in HCD- fed rats. These values represent means and standard errors; the different superscript letters mean a significant difference at P < 0.05 Discussion Research has shown that fish oil can decrease LDL oxidation, with some evidence suggesting that it may also positively impact endothelial health and blood pressure. Additionally, products made with grapes and other berries are often recommended as part of a heart-healthy diet.[17] Cardiometabolic syndrome, a cluster of metabolic abnormalities, increases the risk of CVD.[1] In the present study, we observed greater changes in body weight gain and mean body weight in HCD-fed rats compared to the control rats, which aligns with findings from other studies.[18] Rats on high-fat diets tend to weigh more and develop larger fat pads than those fed standard chow. In our study, HCD not only increased body weight but also induced dyslipidemic changes, including increased triglycerides, total cholesterol, and LDL levels, alongside a decrease in HDL levels [Figure 2]. Fish oil, which contains polyunsaturated fatty acids (PUFAs), particularly its omega-3 fatty acids (EPA and DHA), has been shown to improve glucose and lipid metabolism, cardiac membrane composition, and reduce inflammation. By correcting the dysregulation associated with metabolic syndrome, fish oil may serve as a potential therapeutic target for cardiovascular diseases.[19] However, some studies suggest that omega-3 supplementation might not always improve lipid and morphometric profiles.[20] Fish oil is rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and linolenic omega-3 fatty acids found throughout the body, especially in organs like the heart and brain. These compounds have anti-inflammatory, antioxidant, and vascular protective properties, in addition to helping regulate blood lipids and inhibiting thrombosis.[21] Fatty fish consumption has been shown to improve membrane fluidity and reduce the lipophilic index in individuals with impaired glucose tolerance or coronary heart disease.[22] Fish oil supplementation has significantly reduced serum total cholesterol, LDL cholesterol (LDL-C), and atherogenic index, while increasing HDL-C in hyperlipidemic rabbits. No significant differences were observed in triglyceride levels, VLDL cholesterol, or body weight in either group. This suggests that fish oil has a potent hypolipidemic effect in experimentally induced hyperlipidemia.[23] Fish oil has also been found to reduce proinflammatory cytokine levels, improve insulin resistance, and reduce atherogenic factors in overweight/obese individuals and patients with type 2 diabetes (T2DM), independent of weight loss.[24] In our study, the cardiovascular indices of total cholesterol (TC), LDL, and LDH activity [Figure 2] were higher in the HCD group compared to the normal group, suggesting a connection between HCD and cardiovascular marker disturbances. These effects were ameliorated by the administration of fish oil. Specifically, fish oil reduced serum cholesterol P > 0.05 (87 ± 4.3 to 77 ± 2.4), triglycerides (1.3 ± 0.05 to 1.2 ± 0.096), and LDL P > 0.05 (3.2 ± 0.18 to 2.2 ± 0.2). These changes are likely due to the active ingredients in fish oil. By examining not only lipid profiles (LDL, TG, cholesterol, HDL) but also inflammatory mediators (CRP, TNF, IL-6), the study provides a broader picture of how hypercholesterolemia contributes to metabolic disorders and how fish oil may counteract these effects. The mechanism of fish oil modulates inflammation by reducing the production of inflammatory cytokines biomarkers, CRP, and TNF, which involved in the inflammatory process; also, omega-3 modulates the expression of genes involved in inflammation and oxidative stress. For instance, they can reduce the activity of nuclear factor kappa B (NF-κB), a key regulator of inflammation and oxidative stress. Fish oil and endothelial function Endothelial dysfunction is widely recognized as an early marker of cardiovascular disease, making its prevention or treatment an attractive therapeutic target.[25] Our data showed that a high-cholesterol diet (HCD) significantly increased markers of endothelial dysfunction, whereas fish oil treatment effectively ameliorated these changes, yielding results comparable to atorvastatin treatment at a significant level (P > 0.05) [Figure 5]. Grigore et al.[26] reported that pravastatin, which lowers cholesterol through different mechanisms, improves endothelial function, suggesting that reduced cholesterol levels may contribute to this effect. Accumulating evidence indicates that inflammatory pathways play a critical role in the development and progression of atherosclerosis, with statins being effective in treating endothelial dysfunction by reducing the adhesion of inflammatory cells.[27] Additionally, atorvastatin treatment has been shown to improve endothelial function and reduce inflammatory markers in patients with stable coronary artery disease (CAD).[28] VCAM-1 (vascular cell adhesion molecule-1), encoded by the VCAM1 gene, plays a role in vascular inflammation and serves as a biomarker for predicting cardiovascular disease development, including the persistence of atrial fibrillation.[29] VCAM-1 functions as a cell adhesion molecule, mediating the adhesion of leukocytes to the vascular endothelium and contributing to atherosclerosis development. In response to increased levels of inflammatory biomarkers such as TNF-α and IL-6, VCAM-1 is upregulated in endothelial cells in the HCD groups (P > 0.05).[30] VCAM-1 contributes to atherosclerosis; however, when the endothelial cells lining blood vessels become activated in response to various risk factors like high blood pressure, high cholesterol, smoking, or diabetes, VCAM-1 expression increases. This activation leads to the recruitment of immune cells to the site of injury or damage in the blood vessel walls. VCAM-1 interacts with integrins on the surface of leukocytes, facilitating their adhesion. This adhesion is further induced by proinflammatory cytokines such as IL-1β and TNF-α, which are released in response to C-reactive protein (CRP) produced via IL-6 signaling.[31] This process promotes oxidative low-density lipoprotein (oxLDL) uptake in the arterial intima.[32] IL-6, secreted from activated macrophages, plays a key role in the inflammatory response, contributing to conditions such as pancreatitis, and is recognized as an endogenous pyrogen.[33] The progression of atherosclerosis depends on the differentiation of monocytes into macrophages, and migration through the endothelium into the intima layer of the vessel wall. This is a critical step in the formation of atherosclerotic plaques as monocytes differentiate into macrophages, which engulf lipids and contribute to plaque formation, which promote endothelial dysfunction. This can lead to the development of fatty streaks and eventually more advanced atherosclerotic plaques. The persistent expression of VCAM-1 contributes to the chronic nature of the disease by maintaining the inflammatory environment in the vessel wall. In summary, VCAM-1 levels are closely linked to the initiation and progression of atherosclerosis due to its role in promoting leukocyte recruitment and sustaining inflammation in the vascular endothelium. Elevated VCAM-1 levels are generally associated with more severe forms of atherosclerosis and may serve as both a marker of disease progression and a potential therapeutic target.[34] Inhibiting these processes could serve as an effective defense mechanism against atherosclerosis.[35] Also, this may aid in the development of new therapeutic strategies. As a major regulator of vascular homeostasis, the endothelium exerts vasoprotective effects such as vasodilation, suppression of smooth muscle cell growth, and inhibition of inflammatory responses primarily mediated by nitric oxide (NO). Nitric oxide counteracts vasoconstrictors and inhibits LDL oxidation. A defect in NO production or activity leads to endothelial dysfunction, a hallmark of early-stage atherosclerosis. In our study, increased LDL, VCAM-1, and homocysteine levels, alongside decreased NO, were observed in the HCD group. These findings support the notion that endothelial dysfunction is an early marker of atherosclerosis and a precursor to structural changes in blood vessels. Our study assesses markers such as NOS and VCAM-1, which are not always included in traditional lipid profile studies, providing valuable insights into how hypercholesterolemia affects vascular health and how fish oil may counteract these effects. Additionally, we examined homocysteine levels, an important but sometimes overlooked marker associated with cardiovascular disease risk. Investigating the influence of fish oil on homocysteine levels adds depth to its potential cardioprotective role. Fish oil improves endothelial function by increasing the production of nitric oxide (NO), a molecule that helps dilate blood vessels and maintain vascular tone. Nitric oxide also has antioxidant effects as it scavenges reactive oxygen species (ROS) and prevents endothelial damage. Also, fish oil supports the repair and regeneration of the endothelium, which is crucial for maintaining vascular health.[16] In addition, fish oil improves endothelial health and reduces LDL oxidation through multiple mechanism, includes decreasing oxidative stress, inhibits lipid peroxidation via protecting LDL from oxidative damage, and helps maintain the integrity of LDL particles, reducing their atherogenic potential. Moreover, fish oil alters lipid metabolism to lower triglycerides, improves lipoprotein profiles, reduces platelet aggregation, and promotes vascular repair. These effects collectively contribute to the prevention of cardiovascular diseases by preventing the oxidation of LDL and improving the health and function of blood vessels. Our findings suggest that atorvastatin’s primary mechanism is an HMG-CoA reductase inhibitor, leading to lower LDL level, and reduces the risk of atherosclerosis. However, its pleiotropic effect, as improving endothelial function (P < 0.05), reducing inflammation, providing antithrombotic benefits, improving lipid profiles, VCAM-1, nitric oxide synthase (NOS), and homocysteine levels and offering direct vascular protection, plays a critical role in its cardiovascular protective effects.[1635] These pleiotropic effects help explain why atorvastatin and other statins are effective not only in reducing cholesterol but also in preventing cardiovascular events, even in patients with well-controlled cholesterol levels.[3637] Both atorvastatin and fish oil provide anti-inflammatory and vasodilatory effects, thereby mitigating risk factors for atherosclerosis. The decreased levels of VCAM-1 in the HCD groups, compared to the normal group and other treatment groups, highlight the efficacy of both treatments in improving endothelial function [Figure 5]. While both fish oil and atorvastatin are known for their cardiovascular benefits, this study directly compares their effects on lipid metabolism, inflammatory biomarkers, and endothelial dysfunction markers, offering a clearer understanding of their respective mechanisms. Conclusions HCD-induced hypercholesterolemia and hypertriglyceridemia were improved by both atorvastatin and fish oil. Atorvastatin suppressed hypercholesterolemia by inhibiting HMG-CoA reductase. Our data indicate that HCD feeding increased cardiac and vascular indices, including LDL levels, the LDL/HDL ratio, homocysteine, and VCAM-1, while both atorvastatin and fish oil ameliorated these changes. The study suggests fish oil as a functional dietary ingredient for managing CVD risk, reinforcing the potential of dietary interventions alongside pharmacological treatments like atorvastatin. The findings highlight fish oil’s ability to modulate inflammation and endothelial function, supporting its use as an alternative or adjunct therapy for hypercholesterolemia-induced cardiovascular complications. Fish oil is clinically relevant for improving lipid profiles, reducing inflammation, and enhancing endothelial function, which are key factors in managing cardiovascular disease. It can complement pharmacological treatments like atorvastatin, offering additional benefits in managing high cholesterol and lowering the risk of cardiovascular events. By integrating fish oil into patient care and management plans, clinicians can offer a holistic approach to cardiovascular health, especially in high-risk populations. Institutional animal care and use committee statement All animal procedures in this study were conducted in accordance with the standard guidelines of the Institutional Animal Care and Use Committee, Project IRB No. IRB-2015-10-119 and were funded by the Deanship of Scientific Research at Imam Abdulrahman Bin Faisal, formerly University of Dammam. Conflicts of interest There are no conflicts of interest.